Motif's options22 Sep 2019 21:08
Given that Motif Bio have several other ventured for Iclaprim not just through their ABBSI route shows to me not only the enormous potential but also diversification. For those who are newly invested here. Motif bio also have a partnership with a Scottish company called Llamenar for the use of Iclaprim to treat Cystic Fibrosis, A German university study for the treatment of Toxoplasama a eye infectious diseas and now also another venture to see the effects of treating listeria. Pushing any drug onto the market is never easy and takes years but we have come this far and now we all have to ride this out. A good friend of mine a senior clininical reasearch director told me that CRL's are very common and it will take atleast a year to get approval. lets all be positive for 2020. Good hercules are playing ball too with the Amortization process.